IVIEW THERAPEUTICS
IVIEW Therapeutics is an ophthalmology drug development company that focuses on the treatment of viral conjunctivitis. The company was founded in 2015 by Bo Liang and John Baldwin and is based in Doylestown, Pennsylvania, United States.
IVIEW THERAPEUTICS
Industry:
Biotechnology Health Care Medical Medical Device Therapeutics
Founded:
2015-01-01
Address:
Doylestown, Pennsylvania, United States
Country:
United States
Website Url:
http://www.iviewtherapeutics.com
Total Employee:
1+
Status:
Active
Contact:
267-370-5223
Total Funding:
55.03 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible WordPress Wordpress Plugins Contact Form 7 COVID-19 ASP.NET IIS Sectigo SSL Sectigo Domain SSL
Similar Organizations
1E Therapeutics
1E Therapeutics is a breakthrough, drug development company.
Advanced Chemotherapy Technologies
Advanced Chemotherapy Technologies is a startup developing a device that can infuse chemotherapies into poorly vascularized tumors.
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Interline Therapeutics
Interline Therapeutics is a drug discovery platform that enables the company to map and correct dysfunctional protein communities.
InVivo Therapeutics
InVivo Therapeutics is a medical device company focused on developing restoration treatments for patients with spinal cord-injuries.
Juventas Therapeutics
Juventas Therapeutics is a clinical-stage biotechnology company developing regenerative therapies to treat life threatening diseases.
Kinaset Therapeutics
Kinaset Therapeutics is a therapeutics company that focuses on advancement of novel drugs in areas of unmet medical needs.
Madeira Therapeutics
Madeira Therapeutics is a drug development company specializing in real pediatric medicine by reformulating compounds.
Measurement Analytics
Measurement Analytics, Inc. (MAI) is an intellectual property company that has acquired technology utilization rights.
Mirabilis Medical
Mirabilis Medical is a medical device company that focuses on the treatment of uterine fibroids that is a common problem for women.
Newsoara
Newsoara is a biomedical technology developer that specializes in the development of medical devices.
Noctrix Health
Noctrix Health is an early-stage medical device company that focuses on developing a revolutionary therapy for a chronic illness.
PIC Therapeutics
PIC Therapeutics is a biotechnology company focused on transforming the treatment of cancer.
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Salvia BioElectronics
Salvia is an innovative start-up active in the emerging field of BioElectronics.
Spero Therapeutics
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Syantra
Syantra is a precision healthcare company that focuses on the commercialization of breast cancer detection blood tests.
Treace Medical Concepts
Treace Medical Concepts is a privately-funded development stage company that specializes in foot and ankle surgical products.
uLink Labs
uLink Labs is a medical device company that specializes in next-generation medical devices innovations.
Current Employees Featured
Founder
Investors List
Prox Ventures
Prox Ventures investment in Seed Round - iVIEW Therapeutics
Official Site Inspections
http://www.iviewtherapeutics.com Semrush global rank: 8.69 M Semrush visits lastest month: 266
- Host name: 76.76.21.21
- IP address: 76.76.21.21
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "iVIEW Therapeutics"
Becoming a Leader in Ophthalmic Therapeutics
IVIEW Therapeutics Inc. is a clinical stage biotechnology company focusing on innovative ophthalmic therapeutics. We are driven by the pursuit of innovative science that leads to …See details»
iView Therapeutics |Becoming a Leader in Ophthalmic …
2024-09-17. IVIEW Therapeutics Inc. Completes Patient Recruitment for Phase 1/2 Trial of IVW-1001 Ophthalmic Eyelid Wipe in Dry Eye Disease PatientsSee details»
iVIEW Therapeutics - Crunchbase Company Profile
IVIEW Therapeutics is an ophthalmology drug development company that focuses on the treatment of viral conjunctivitis. The company was founded in 2015 by Bo Liang and John Baldwin and is based in Doylestown, …See details»
IView Therapeutics - LinkedIn
IVIEW Therapeutics Inc. is a clinical stage ophthalmology drug development company. Our novel drug development strategies are centered in: - Novel extended-release formulations - Combination ...See details»
Becoming a Leader in Ophthalmic Therapeutics
Becoming a Leader in Ophthalmic Therapeutics. iVIEW is committed to protecting your privacy and the security of the information which you share with us.See details»
iView Therapeutics - PitchBook
IView Therapeutics General Information Description. Developer of topical drugs designed for applications in ophthalmology, dermatology, and otolaryngology. The company develops drugs including long-acting povidone-iodine ophthalmic …See details»
FDA clears iView Therapeutics IND application to start …
Mar 12, 2024 iView Therapeutics announced the US Food and Drug Administration (FDA) cleared the company’s Investigational New Drug (IND) application for the initiation of a Phase 1/2 clinical trial as “safe to proceed.” 1 …See details»
IVIEW Therapeutics Inc - VentureRadar
Similar Companies: Sun BioPharma USA Privately Held Sun BioPharma is developing small-molecule pharmaceuticals consisting of novel polyamine analogues and metal chelators, and …See details»
iVIEW Therapeutics announces a successful pre-IND meeting
Plans to develop this novel compound. This shows con fidence in our team and our preclinical and clinical plans to advance IVW- 1001 to treat dry eye disease.See details»
Becoming a Leader in Ophthalmic Therapeutics
[Cranbury, NJ, March 11, 2024] iView Therapeutics Inc., a clinical stage biotechnology company dedicated to advancing innovative treatments for ocular diseases, announces that the U.S. …See details»
iView Therapeutics completes enrollment in phase 1/2 trial for ...
Sep 18, 2024 iView Therapeutics Inc has completed patient recruitment for its Phase 1/2 clinical trial (NCT06400459) evaluating IVW-1001 for the signs and symptoms of dry eye disease …See details»
iView Therapeutics Inc. Announced FDA’s Clearance of IND
Dry eye diseases represent a prevalent and burdensome condition affecting millions worldwide. IVW-1001, developed by iView Therapeutics Inc., offers promising potential as a therapeuticSee details»
iView Announces First Patient Treated in Phase 2 Clinical Trial …
Dec 20, 2019 For additional information on iView, please visit the Company's website at www.iviewtherapeutics.com. CONTACT: David Hiller , 615-724-4012, [email protected] …See details»
iView Announces First Patient Treated in Phase 2 Clinical
Dec 19, 2019 iView Therapeutics Inc. is a clinical stage biopharmaceutical company focused on t he discovery, development and commercialization of ophthalmology therapeutics. iVIEWSee details»
Becoming a Leader in Ophthalmic Therapeutics
I-Gel In-situ Gel Technology. The I-GEL extend release technology is a novel in-situ gel delivery platform, which presents unique properties of sol-gel phase transition on receipt of biological …See details»
IVIEW Therapeutics Inc. Completes Patient Recruitment for Phase …
CRANBURY, N.J., Sept. 17, 2024 /PRNewswire/ — IVIEW Therapeutics Inc., a clinical-stage biotechnology company dedicated to advancing innovative treatments for ocular diseases, …See details»
iView Announces First Patient Treated in Phase 2 Clinical Trial …
Dec 20, 2019 For additional information on iView, please visit the Company's website at www.iviewtherapeutics.com. CONTACT: David Hiller , 615-724-4012, [email protected] …See details»
Becoming a Leader in Ophthalmic Therapeutics
2024-06-25. IVIEW Therapeutics Inc. Announces Dosing of First Patient in Phase 1/2 Clinical Trial of IVW-1001 for Dry Eye Disease. Read MoreSee details»
iVIEW announces Completion of First Patient Treatment in Phase II ...
CRO organization with extensive ophthalmology clinical research experience commented; “If this drug is marketed, it will significantly change the treatment choices of bacterial conjunctivitis …See details»
Becoming a Leader in Ophthalmic Therapeutics
Jan 30, 2023 2024-04-17. IVIEW Therapeutics Completed Successful IVW-1001-CS-101 Clinical Trial Kickoff Meeting and Expects to Initiate the Trial In Q2 2024See details»